Eli Lilly and Company (NYSE:LLY) Receives $353.59 Consensus Price Target from Brokerages

Eli Lilly and Company (NYSE:LLYGet Rating) has earned an average rating of “Moderate Buy” from the nineteen analysts that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $359.78.

A number of equities analysts have recently commented on LLY shares. BMO Capital Markets boosted their price target on Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a report on Tuesday, September 6th. Wells Fargo & Company upped their target price on Eli Lilly and from $305.00 to $365.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 2nd. Barclays upped their target price on Eli Lilly and from $355.00 to $395.00 and gave the stock an “overweight” rating in a report on Wednesday, November 2nd. Berenberg Bank upped their target price on Eli Lilly and from $345.00 to $375.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Credit Suisse Group started coverage on Eli Lilly and in a report on Thursday, November 17th. They issued an “outperform” rating and a $395.00 target price for the company.

Eli Lilly and Price Performance

Eli Lilly and stock opened at $361.72 on Friday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.88 and a current ratio of 1.13. Eli Lilly and has a 52 week low of $231.87 and a 52 week high of $369.80. The stock has a market capitalization of $343.70 billion, a P/E ratio of 54.31, a price-to-earnings-growth ratio of 2.28 and a beta of 0.36. The stock has a fifty day moving average of $338.86 and a 200-day moving average of $321.23.

Eli Lilly and Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be given a dividend of $0.98 per share. The ex-dividend date of this dividend is Monday, November 14th. This represents a $3.92 annualized dividend and a dividend yield of 1.08%. Eli Lilly and’s payout ratio is 58.86%.

Insider Activity at Eli Lilly and

In related news, major shareholder Lilly Endowment Inc sold 101,631 shares of the company’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $335.07, for a total transaction of $34,053,499.17. Following the sale, the insider now owns 103,773,810 shares in the company, valued at approximately $34,771,490,516.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Alonzo Weems sold 656 shares of the company’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $326.23, for a total transaction of $214,006.88. Following the sale, the executive vice president now owns 6,950 shares in the company, valued at approximately $2,267,298.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 101,631 shares of the stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $335.07, for a total value of $34,053,499.17. Following the completion of the transaction, the insider now owns 103,773,810 shares in the company, valued at approximately $34,771,490,516.70. The disclosure for this sale can be found here. Insiders have sold a total of 571,297 shares of company stock worth $193,929,777 in the last 90 days. Corporate insiders own 0.12% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Insight Inv LLC purchased a new stake in shares of Eli Lilly and in the second quarter worth approximately $26,000. Cordant Inc. purchased a new stake in shares of Eli Lilly and in the first quarter worth approximately $25,000. Castle Wealth Management LLC purchased a new stake in shares of Eli Lilly and in the second quarter worth approximately $28,000. Horan Securities Inc. raised its stake in shares of Eli Lilly and by 96.0% in the second quarter. Horan Securities Inc. now owns 98 shares of the company’s stock worth $32,000 after purchasing an additional 48 shares during the last quarter. Finally, Cypress Capital Management LLC WY raised its stake in shares of Eli Lilly and by 300.0% in the second quarter. Cypress Capital Management LLC WY now owns 100 shares of the company’s stock worth $32,000 after purchasing an additional 75 shares during the last quarter. Institutional investors own 82.45% of the company’s stock.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.